An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer

BACKGROUND: Classifying the progression pattern had been proved to be momentous for predicting efficacy and guiding treatment in the 1st/2nd generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), while lack evidence in the 3rd generation EGFR-TKIs. This study aimed to cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yue, Jiang, Yingying, Pan, Banzhou, Wang, Zihan, Li, Hang, Ma, Yuxin, Liu, Yilin, He, Kang, Wang, Zhitong, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Yin, Rong, Rossi, Antonio, Ito, Kentaro, Santarpia, Mariacarmela, Um, Sang-Won, Wang, Xiaohua, Chen, Cheng, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186173/
https://www.ncbi.nlm.nih.gov/pubmed/35693279
http://dx.doi.org/10.21037/tlcr-22-315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186173/
https://www.ncbi.nlm.nih.gov/pubmed/35693279
http://dx.doi.org/10.21037/tlcr-22-315

Ejemplares similares